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The NF2 tumor suppressor regulates microtubule-based vesicle
trafﬁcking via a novel Rac, MLK and p38SAPK pathway
RF Hennigan1, CA Moon1, LM Parysek2, KR Monk3, G Morfini4,5, S Berth4,5, S Brady4,5,6 and N Ratner1,5,6
Neuroﬁbromatosis type 2 patients develop schwannomas, meningiomas and ependymomas resulting from mutations in the tumor
suppressor gene, NF2, encoding a membrane-cytoskeleton adapter protein called merlin. Merlin regulates contact inhibition of
growth and controls the availability of growth factor receptors at the cell surface. We tested if microtubule-based vesicular
trafﬁcking might be a mechanism by which merlin acts. We found that schwannoma cells, containing merlin mutations and
constitutive activation of the Rho/Rac family of GTPases, had decreased intracellular vesicular trafﬁcking relative to normal human
Schwann cells. In Nf2 / mouse Schwann (SC4) cells, re-expression of merlin as well as inhibition of Rac or its effector kinases,
MLK and p38SAPK, each increased the velocity of Rab6 positive exocytic vesicles. Conversely, an activated Rac mutant decreased
Rab6 vesicle velocity. Vesicle motility assays in isolated squid axoplasm further demonstrated that both mutant merlin and active
Rac speciﬁcally reduce anterograde microtubule-based transport of vesicles dependent upon the activity of p38SAPK kinase. Taken
together, our data suggest loss of merlin results in the Rac-dependent decrease of anterograde trafﬁcking of exocytic vesicles,
representing a possible mechanism controlling the concentration of growth factor receptors at the cell surface.
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INTRODUCTION
Neuroﬁbromatosis type 2 is an inherited autosomal dominant
disease characterized by bilateral schwannomas of the 8th cranial
nerve.1–3 The tumor suppressor gene responsible for this disorder,
NF2, is also inactivated in spontaneously arising tumors, including
schwannoma, meningioma and malignant mesothelioma, thus
implicating it in a range of human cancers.4 Targeted deletion of
Nf2 in Schwann cells leads to schwannoma formation in the
mouse.5 The NF2 gene encodes merlin, a 70-kDa member of the
ezrin, radixin, moesin (ERM) family of membrane-cytoskeleton
adapter proteins. The precise mechanisms by which merlin
functions as a tumor suppressor are poorly understood.
Merlin shares a conserved secondary structure with other
members of the ERM family consisting of an N-terminal FERM
domain, followed by a central a-helical region and a C-tail
domain.6 Transition between the open, FERM-accessible
conformation and the closed, FERM-inaccessible conformation
controls merlin tumor suppressor function and is modulated
by phosphorylation of serine 518.7 Phosphorylation of S518
correlates with a growth-permissive state and is a key point of
integration of merlin activity with signal transduction pathways.8,9
Under growth-suppressive conditions, merlin is activated upon
dephosphorylation of S518 by cellular phosphatases such as
MYPT1-PP1d.10 Inactivation of merlin is achieved by the action of
the small GTPase, Rac, via its effector kinase, PAK, resulting in
phosphorylation of merlin at S518.11,12 Merlin in turn antagonizes
Rac activity by an unknown mechanism, forming a negative
feedback loop of mutual inhibition.13 This antagonism appears to
be lost in human schwannomas because these merlin-deﬁcient
cells are characterized by constitutive activation of Rac.14–16
Nf2-null cells grow to abnormally high densities in vitro, and it has
been suggested that this loss of contact inhibition is the biological
basis for schwannoma formation.17,18 Merlin is thought to control
contact inhibition by regulating the cell surface availability
of growth factor receptors.19,20 However, the mechanisms by
which merlin, and perhaps activated Rac, affects growth factor
receptor abundance are unclear.
We found that merlin-deﬁcient tumor cells show decreased
intracellular vesicular trafﬁcking relative to normal human
Schwann cells. Signiﬁcantly, this effect was dependent upon the
activity of Rac and the MAP kinase p38SAPK. Inhibition of Rac and
the effector kinase MLK3 also impaired growth in merlin null cells
at high density. In Nf2 / SC4 Schwann cells, re-expression of
merlin or inhibition of Rac, MLK or p38SAPK all resulted in increased
velocity of exocytic vesicles. In a squid axoplasm system, open
conformation mutants of merlin and active Rac each speciﬁcally
reduced fast anterograde axonal vesicle transport. This effect was
independent of the plasma membrane and dependent upon the
activity of p38SAPK. Together these data show that the loss of
merlin reduces microtubule-based exocytic vesicle velocity in a
Rac-MLK-p38SAPK-dependent manner. We propose that merlin-Rac
signaling may normally modulate vesicle release from micro-
tubules, inﬂuencing concentrations of growth factor receptors at
the cell surface.
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RESULTS
VAMP-2 vesicle mobility is reduced in schwannoma cells in a
Rac- and p38SAPK-dependent manner
To determine if loss of merlin expression affects intracellular
vesicular trafﬁcking, we designed an assay to measure the
mobility of a subset of membrane-bounded organelles in live
primary normal human Schwann cells relative to live, patient-
derived primary human schwannoma cells. To visualize internal
vesicle motion by time-lapse imaging, we marked transfected cells
with a plasmid expressing GFP fused to the ubiquitously
expressed v-SNARE protein, VAMP2/synaptobrevin 2.21–24 The
relative mobility of VAMP2-GFP-positive vesicles was used as a
measure of general intracellular trafﬁcking (Figure 1). Primary
cultures were transfected with plasmids expressing a VAMP2-GFP
fusion protein and general mobility was quantiﬁed by measuring
the percentage of VAMP2-GFP-positive vesicles that changed
position between successive 3 s intervals over 180 s. Normal
human Schwann cells showed highly motile VAMP2-positive
vesicles with a broad range of values, (Figure 1c) with a mean
and s.e.m. of 4.2±0.1%. In contrast, primary human schwannoma
cells had a more restricted range of values (Figure 1d), with a
mean and s.e.m. of 2.0±0.1%, suggesting an inhibition of
intracellular membrane trafﬁc in tumor relative to normal cells.
As loss of merlin expression results in activation of Rac,13 we
measured VAMP-2 in schwannoma cells treated with the speciﬁc
Rac inhibitor NSC23766.25 Rac inhibition signiﬁcantly increased
VAMP-2 mobility (Figure 1e), mean and s.e.m. of 6.0±0.1%. The
MAP kinase, p38SAPK functions downstream of Rac and has been
shown to phosphorylate and inhibit kinesin heavy chain, thereby
implicating it in the regulation of trafﬁcking.26 Treatment of
schwannoma cells with the p38SAPK inhibitor, SB203580,
signiﬁcantly increased VAMP-2 mobility (Figure 1f), mean and
s.e.m. of 5.8±0.1%. These data implicated a Rac-p38SAPK pathway
as regulating intracellular trafﬁcking in schwannoma cells.
Rac regulates high density growth in merlin null cells
The results of the VAMP2 experiments suggested that Rac controls
a p38SAPK-dependent pathway that regulates intracellular vesicle
motility. We next tested if this pathway was required to mediate
the major biological consequence of merlin mutation, loss of
contact inhibition of growth.27 Nf2 / merlin-deﬁcient
Figure 1. Inhibition of Rac and p38 increases VAMP2-positive vesicle mobility in merlin-null schwannoma. Human schwannoma cells
transfected with VAMP-2-GFP-expressing plasmid display a large number of discrete intracellular vesicles (a). The cumulative vesicle motility is
depicted by combining all images of the time lapse from live cells that were imaged at 3 s intervals for a total of 3min (b). Frequency
histograms show the mobile fraction of VAMP2-GFP vesicles per 3 s interval. (c) NHSC, mean±s.e.m.: 4.2±0.1. (d) Schwannoma, mean±s.e.m.:
2.0±0.1. (e) SchwannomaþNSC23766, mean±s.e.m.: 6.0±0.1. (f ) Schwannomaþ SB203580, mean±s.e.m.: 5.8±0.1.
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ﬁbroblasts grow to much higher densities than Nf2þ /þ cells,
demonstrating merlin-dependent contact inhibition of growth
(Figure 2). Treatment with the Rac inhibitor, NSC23766, did not
alter growth rates at low density but did signiﬁcantly inhibit
growth of Nf2 / cells once they achieved high density
(Figure 2a). Growth rates of Nf2þ /þ cells were unaffected by
NSC23766 (Figure 2a). Similarly, CEP11004, an inhibitor of the
mixed lineage kinases family (MLK), a Rac effector kinase that
regulates p38SAPK activity28 also speciﬁcally inhibited growth once
Nf2 / cells achieve high density, but did not affect Nf2þ /þ
cells (Figure 2b). The p38SAPK inhibitor, SB203580, slowed growth
in Nf2 / at high density but also suppressed the growth rate in
Nf2þ /þ cells (Figure 2c). These data suggest that the same signal
transduction pathways that affect trafﬁcking are involved in
merlin-dependent contact inhibition of growth.
Rab6 is a marker for exocytic vesicles in merlin-deﬁcient schwann
cells
The VAMP2-GFP experiments suggested that merlin may regulate
intracellular trafﬁcking via Rac in a p38SAPK-dependent manner,
possibly implicating constitutive exocytosis.29 We therefore
developed a system to speciﬁcally measure constitutive
exocytosis in an immortalized, transformed merlin-null Schwann
cell line, SC4. We used plasmids expressing Rab6 fused to the
red ﬂuorescent protein variant mStrawberry as a marker for
constitutive exocytosis.30 To conﬁrm that Rab6 exocytic vesicles
carry a cargo relevant to Schwann cells, we cotransfected SC4 cells
with plasmids expressing Rab6-mStrawberry and a ErbB2-GFP
construct.31 Images were acquired from live SC4 cells maintained
at 37 1C 6 h after transfection, before the bulk of the newly
synthesized ErbB2-GFP establishes itself in the plasma membrane.
Under these conditions Rab6 was localized primarily to the Golgi
with a minority expressed in multiple small vesicles dispersed
throughout the cytoplasm (Figure 3a). ErbB2 had plasma
membrane localization and a signiﬁcant amount of nascent
ErbB2-GFP in the Golgi but was also localized to small vesicles
dispersed within the cytoplasm (Figures 3a and b). A subpopula-
tion of ErbB2-expressing vesicles colocalized with Rab6 vesicles
(Figures 3b and c). Time-lapse images of live cells also identiﬁed
double positive vesicles moving towards the plasma membrane
(Supplementary Movie 1). This indicates that a subset of Rab6
positive, post-Golgi vesicles carry the relevant ErbB2 cargo, and
conﬁrm Rab6 as a marker of constitutive exocytosis in this system.
Regulation of Rab6 vesicle velocity by the Merlin-Rac-MLK3-
p38SAPK pathway
To measure the motion of exocytic Rab6 vesicles, we performed
live-cell time-lapse experiments in SC4 cells, maintained at 37 1C
(Supplementary Movie 2). A single frame of a representative time
lapse shows intense signal in the Golgi with numerous small
vesicles dispersed within the cytoplasm (Figure 4a). To visualize
motion, all images of the time lapse (60 s) were collated into a
single image. This procedure revealed a network of vesicle tracks
extending from the Golgi to the plasma membrane, a pattern
consistent with vesicles moving along the microtubule network
(Figure 4b). To aid in tracking speciﬁc vesicles and establish their
anterograde direction, time-lapse stacks were color coded to
display three successive frames in red, green and blue, then the
velocity of individual vesicles was measured (Figure 4c,
Supplementary Movie 2).
To test whether merlin loss affects Rab6 vesicle velocity,
Nf2 / SC4 cells were cotransfected with plasmids expressing
Rab6-mStrawberry and either merlin or empty vector, then
velocities were measured as described above. The average
Figure 2. Rac activity specifically regulates high density growth in NF2 null fibroblasts. Immortalized Nf2þ /þ and Nf2 / fibroblasts were
plated at low density and allowed to grow to saturation density for 5–6 days in the presence or absence of inhibitors to (a) Rac, 100 mM
NSC23766 (b) MLK, 10mM CEP11004 and (c) p38SAPK, 10mM SB203580.
Figure 3. Rab6 vesicles carry ErbB2 cargo. (a) Live SC4 cells cotransfected with ErbB2-GFP (green) and Rab6-mStrawberry (red) -expressing
plasmids. The box identifies the region shown at high magnification for ErbB2-GFP (b) and Rab6-mStrawberry (c). The arrows indicate a subset
of Rab6-positive intracellular vesicles that contain ErbB2-GFP.
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velocities of 200–500 vesicle tracks per condition were calculated.
Re-expression of merlin caused a reproducible shift to a faster
moving population of Rab6 vesicles compared to empty vector
(Figure 5a). Inhibition of Rac using 100mM NSC23766 increased
vesicle velocity to a similar degree that merlin transfection did
(Figure 5b). This suggests that merlin expression in live cells
suppresses Rac activity, thereby controlling Rab6 vesicle velocity.
Conversely, transfection with a hyperactive fast cycling Rac
mutant, F28L, caused a signiﬁcant decrease in Rab6 vesicle
velocity (Figure 5c), consistent with Rac activity acting as a brake
on exocytic transport. Interestingly, a constitutively GTP bound,
active Rac mutant, Q61L, did not affect Rab6 velocity (Figure 5d),
suggesting that the ability of Rac to cycle from the GDP to the
GTP-bound states is critical to this regulation. Interestingly, we
found that Rac-GTP colocalized with microtubules in SC4 cells
(Supplementary Figure 1), consistent with previous reports that
Rac-GTP binds to tubulin polymers.32 These data place active Rac
in a position to inﬂuence exocytic vesicle transport.
Next, we examined the role of MLK and p38SAPK on exocytic
vesicle mobility. Treatment of SC4 cells with the MLK inhibitor
CEP11004 increased Rab6 vesicle velocity (Figure 5e), indicating
that a member of the MLK family participates in this regulatory
pathway. Inhibition of p38SAPK with 20 mM SB203580 also increased
Rab6 vesicle velocity (Figure 5f). Taken together these data
provide compelling evidence that merlin regulates constitutive
exocytosis via a Rac, MLK, p38SAPK-mediated pathway.
Open conformation merlin mutants slow anterograde fast axonal
transport
To directly assess the effect of Merlin and Rac on microtubule-
dependent vesicle trafﬁc, we used vesicle motility assays in
isolated squid axoplasm. This experimental system allows for
quantitative analysis of fast axonal transport in both anterograde
(conventional kinesin-dependent) and retrograde (cytoplasmic
dynein-dependent) in the absence of the plasma membrane.33
Vesicle motility assays in isolated axoplasm were instrumental in
the original discovery of conventional kinesin34 and novel
regulatory pathways for microtubule-based vesicle transport.35,36
Perfusion of squid axoplasm with 1 mM puriﬁed recombinant
wild-type merlin protein had little or no inhibitory effect on the
velocity of membrane-bound organelles in the anterograde
direction over the 50-min assay period (Figure 6a). We then
tested FERM-Helix, a C-terminal deletion mutant of merlin
containing amino acids 1–502, that was shown to be FERM
accessible relative to wild type by virtue of increased interaction
with NHERF.7 Perfusion with the FERM-Helix mutant signiﬁcantly
reduced anterograde vesicle velocity (Figure 6b). Inhibition of
p38SAPK activity by coperfusion with the SB203580 inhibitor
rescued anterograde vesicle inhibition by the FERM-Helix mutant
(Figure 6c). Perfusing a non-phosphorylatable mutant, S518A, had
little or no effect on vesicle velocity in this system (Figure 6d), a
similar response to wild type. A phosphomimetic mutant S518D,
which is predicted to have an accessible FERM domain and fails to
suppress cell growth,13 also reduced anterograde vesicle transport
(Figure 6e). This effect was not rescued by SB203580, suggesting
different mechanisms of inhibition between FERM-Helix and
S518D (Figure 6f). Retrograde velocity was essentially unchanged
in all proteins tested. These data suggest that the open, FERM-
accessible isoforms of merlin, FERM-Helix and S518D can
speciﬁcally regulate kinesin-mediated anterograde vesicle trans-
port. This inhibition occurs in the cell-free squid axoplasm system
and is thus independent of the plasma membrane, where the bulk
of merlin is localized, and of the cell nucleus, another reported site
of merlin action.37 The dependence of FERM-Helix inhibition of
anterograde vesicle transport on p38SAPK activity indicates that
suppression is mediated by a kinase chain initiated by merlin,
leading to a reduction in anterograde vesicle velocity.
Figure 4. Rab6 exocytic vesicle velocity measurement in live SC4 cells. (a) A single frame from a time-lapse SC4 cells transfected with plasmid
expressing Rab6-mStrawberry, imaged at 1 s intervals for 1min. (b) Total mobile vesicles depicted by subtracting the minimum pixel
projection from the maximum pixel projection. (c) Five frames of the time lapse from the region of interest in b, processed to facilitate tracking
individual vesicles, are shown with successive frames in red, green and blue. The arrow and bar indicates the progress of an individual vesicle
over a 10-s time frame.
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Rac regulates anterograde fast axonal transport via p38SAPK
It is striking that the merlin mutants that inhibit anterograde
vesicle transport are predicted to have an open, FERM-accessible
conformation and a growth-permissive phenotype. The growth-
permissive phenotype correlates with the higher levels of active
Rac-GTP, seen in schwannoma cells. In contrast, isoforms that do
not affect vesicle transport are predicted to have a closed, FERM-
blocked conformation, have a growth-suppression phenotype that
correlates with low levels of Rac-GTP. We therefore tested the
effect of Rac on anterograde vesicle transport. Perfusion of squid
axoplasm with 1 mM active Q61LRac caused a signiﬁcant and
speciﬁc reduction in anterograde vesicle transport (Figure 7a).
Retrograde transport was unaffected. As with the merlin proteins,
inhibition of p38SAPK reversed the effect of Q61L Rac (Figure 7b),
suggesting that it functions in the same pathway as merlin to
regulate anterograde transport. This effect was speciﬁc for active
Rac as perfusion with dominant negative N17Rac mutant protein
failed to affect either anterograde or retrograde transport
(Figure 7c). The effect was also speciﬁc for Rac, as perfusion with
recombinant active V12 Ras did not affect vesicle transport in
either direction (Figure 7c). These results suggest that merlin
regulates Rac to control a p38SAPK-dependent pathway that
speciﬁcally regulates anterograde trafﬁcking (Figure 8). Collec-
tively, results from our experiments indicate that the loss of merlin
increases Rac activity, which, in turn, promotes activation of the
MLK/p38 kinase pathway, ultimately resulting in the inhibition of
anterograde vesicle motility.
DISCUSSION
At the cellular level, merlin function is critical for contact inhibition
of growth,8,17 as illustrated by the continued proliferation of Nf2
null ﬁbroblasts at high cell density,27 yet the speciﬁc biochemical
functions that merlin performs remain uncertain. Growing
evidence suggests that merlin may control some aspect of
intracellular vesicle trafﬁcking.29,38,39 We hypothesized that
merlin regulates anterograde vesicle trafﬁcking and designed a
set of experiments to test this hypothesis in the context of live
mammalian cells as well as in a plasma membrane-free axoplasm
system. Our data suggest that in the absence of merlin active
Figure 5. Rab6 vesicle velocity is regulated by a Merlin-Rac pathway. The velocities of anterograde Rab6-mStrawberry exocytic vesicles in
transfected SC4 cells displayed as both frequency histograms (left) and a bar graph of mean velocities with the 95% confidence interval (right).
(a) SC4 cells cotransfected with Rab6-mStrawberry and either a merlin-expressing plasmid or empty vector. (b) SC4 cells treated for 2–3 h with
100 mM of the Rac inhibitor NSC23766. (c) SC4 cells cotransfected with Rab6-mStrawberry and either an active, fast cycling F28L-Rac mutant-
expressing plasmid or empty vector. (d) SC4 cells cotransfected with Rab6-mStrawberry and either a constitutively GTP-bound Q61L-Rac
mutant-expressing plasmid or empty vector. (e) SC4 cells treated for 2–3 h with 100 nM of the MLK inhibitor CEP11004. (f ) SC4 cells treated for
2–3 h with 20 mM of the p38SAPK inhibitor SB203580.
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Rac slows kinesin motor-driven transport of vesicles along
microtubules. Consistent with this activity, Rac was recently
reported to antagonize the function of the mitotic kinesin, Eg5,
at microtubule asters during metaphase.40 This, together with our
data, suggests that Rac-mediated signaling pathways may
regulate multiple members of the kinesin family.
Our ﬁnding that decreased intracellular vesicular trafﬁcking in
primary human NF2 schwannoma cells relative to primary normal
human Schwann cells was dependent on Rac, and p38SAPK
identiﬁes a novel pathway regulating transport. Notably,
the active inhibition of trafﬁcking in merlin-deﬁcient cells by a
Rac- and p38SAPK-mediated signaling pathway correlated
with restored contact inhibition of growth in merlin null
ﬁbroblasts, suggesting that this pathway is critical to merlin
function. Trafﬁcking experiments in primary human schwannoma
cells ensured that the trafﬁcking phenotype is relevant to
tumor pathobiology. However, as tumors are the end result
of a multi-hit progression, we could not unambiguously attribute
changes in vesicle motility to the loss of merlin. Also,
because VAMP-2 does not discriminate among different
types of intracellular vesicle trafﬁcking,41 we could not identify
the speciﬁc molecular systems responsible for changes in
vesicle mobility. To address these issues, we designed an
experimental system to directly test the effect of merlin on
constitutive exocytosis, one of the trafﬁcking modalities
implicated in NF2.29
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Figure 6. Merlin inhibits anterograde axonal transport in isolated squid axoplasm. Membrane-bound organelle velocities were measured after
perfusion of axoplasm with buffer supplemented with 0.5–1 mM purified recombinant merlin, or recombinant merlin plus the p38SAPK inhibitor,
SB203580. Anterograde (blue) and retrograde (red) velocity measurements taken between 25 and 45min were plotted as points. Curves were
fitted for anterograde movement and retrograde movement using an exponential curve fit. (a) Full length, wild-type merlin. (b) C-terminal tail
domain deletion mutant, FERM-Helix. (c) FERM-Helix plus SB203580. (d) The phosphorylation site mutant S518A. (e) The phosphomimetic
mutant S518D. (f ) The S518D mutant plus SB203580.
Figure 7. Active Rac inhibits anterograde axonal transport in isolated squid axoplasm. (a) 1 mM purified recombinant active Q61L Rac. (b) Q61L
Rac, treated with the p38SAPK inhibitor, SB203580. (c) Dominant negative N17 Rac failed to inhibit anterograde (blue) or retrograde (green).
Recombinant active V12 Ha-Ras also failed to inhibit anterograde (red) or retrograde (yellow) transport.
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We used a genetically encoded, ﬂuorescent Rab6-mStrawberry
fusion protein to record the trafﬁcking of exocytic vesicles from
the Golgi to the plasma membrane.30 This system focused our
analysis on anterograde vesicle movement along microtubules, a
direct measure of kinesin motor function in live mammalian cells.
Re-expression of merlin or Rac inhibition in Nf2 / SC4
Schwann cells increased Rab6 vesicle velocity. The surprising
association of the Rac pathway with vesicle trafﬁcking is
strengthened by our ﬁnding that inhibition of downstream Rac
effectors, MLK and p38SAPK, also signiﬁcantly increased Rab6
vesicle velocity.
A fast-cycling mutant of Rac, F28L, decreased Rab6 vesicle
velocity, providing compelling positive evidence that Rac acts to
antagonize anterograde vesicular trafﬁcking. The failure of the
constitutive GTP-bound Rac mutant Q61L to reduce vesicle
velocity in mammalian cells implies that a speciﬁc guanine
exchange factor is required, most likely to bind and activate Rac at
speciﬁc subcellular sites.42 In contrast, in the squid axoplasm
the Rac Q61L did show slow transport. In this case, perfusion of
GTP-Rac directly into the axoplasm likely obviated a requirement
for nucleotide exchange factors to localize Rac. These results
(1) conﬁrm experiments performed in primary schwannoma cells,
(2) demonstrate that loss of merlin is sufﬁcient to impair
anterograde trafﬁcking and (3) identify a pathway consisting of
merlin, Rac, MLK and p38SAPK that modulates microtubule-based
trafﬁcking.
The kinesin motor protein heavy chain is a substrate for
p38SAPK,26 and kinesin phosphorylation is the most likely
mechanism responsible for changes in vesicle kinetics that we
describe. A member of the MAP kinase family, p38SAPK is activated
by the intermediary kinases, MKK4 and MKK6, which in turn may
be activated by MLK.43,44 MLK itself is activated by binding to Rac-
GTP or cdc42-GTP.45 It is interesting to note that the MLK family
member MLK2 can interact with microtubules and complex with
the kinesin Kif3,46 supporting the idea that a Rac-MLK-p38SAPK
pathway may have a central role in regulating trafﬁcking of
multiple motors.
Use of a plasma membrane-free axoplasm isolated from the
giant axon of the Atlantic squid Loligo pealei allowed us to
distinguish between merlin exerting a direct effect at the level of
the microtubules or vesicles and an indirect event caused by
merlin regulating upstream signal transduction events originating
at the plasma membrane or in the nucleus. Our ﬁnding that
perfusion of merlin mutants speciﬁcally inhibited anterograde
transport, argued for a direct regulation of trafﬁcking at the level
of microtubules. More signiﬁcantly this data is consistent with
recent reports in the literature, suggesting that merlin interacts
with microtubules and promotes tubulin polymerization.47 In
Drosophila, merlin is expressed in cytoplasmic particles that move
along microtubules via interaction with kinesin and dynein motor
proteins.48 Inhibition of anterograde trafﬁcking was restricted to
the open conformation mutants of merlin, the FERM-Helix domain
and S518D. For the FERM-Helix mutant, treatment with the
p38SAPK inhibitor SB203580 abrogated this inhibition, conﬁrming
that merlin’s effect was dependent on a kinase-based signal
transduction cascade, most likely targeting the kinesin motor
protein complex. The SB203580 did not rescue inhibition by the
S518D, suggesting some other mechanism action for this mutant.
Regardless of the speciﬁc mechanism of action, these intriguing
results suggest that presumably growth-permissive forms of
merlin may have an active role in orchestrating membrane
trafﬁcking during cell growth.
Figure 8. Model for merlin-Rac-p38SAPK regulation of kinesin. A schematic diagram depicting the molecular pathways influenced by merlin
and activated Rac that regulate anterograde exocytic vesicle movement by phosphorylation of kinesin heavy chain mediated by the MLK-
p38SAPK kinase module.
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Microtubule-based trafﬁcking is critical for selective delivery of
membrane proteins to speciﬁc cellular domains in normal cells
and tissues. Changes in the regulation of microtubule-based
trafﬁcking that alter localization of speciﬁc growth factor receptors
may be one mechanism by which loss of merlin disrupts contact
inhibition of growth. This is consistent with previous observations
that merlin regulated growth factor availability,19,39 endocytosis38
and exocytosis.29 Microtubule-based trafﬁcking may have other
critical roles in oncogenesis as well. This idea is supported by the
fact that activation of kinase-mediated pathways is universal in
tumor cells, and recent ﬁndings show that many of these same
kinases can also affect trafﬁcking. It is therefore of considerable
interest to explore this novel relationship between microtubule-
based trafﬁcking and cancer.
MATERIALS AND METHODS
Inhibitors
The MLK inhibitor CEP11004 (Cephalon, Frazer, PA, USA) was used at
200 nM ﬁnal concentration from a 100-mM stock in DMSO. The Rac inhibitor,
NSC23766, was a gift from Dr Yi Zheng (Cincinnati Children’s Hospital,
Cincinnati, OH, USA) used at 100mM ﬁnal concentration from a 100-mM
aqueous stock. The p38SAPK inhibitor SB203580 (Calbiochem, San Diego,
CA, USA) was used at 100mM ﬁnal concentration from a 100-mM stock
in DMSO.
Plasmids
A plasmid expressing the mStrawberry-Rab6 fusion protein30 was a kind
gift from Dr Anna Akhmanova (Erasmus Medical Center, Rotterdam, The
Netherlands). ErbB2 was visualized using pYEC, a gift from Dr Bo van Deus
(University of Copenhagen, Copenhagen, Denmark). pYEC expresses a
YFP-ErbB2-CFP fusion protein49 and is referred to in the text as ErbB2-GFP.
Rac Q61L (Dr Yi Zheng, Cincinnati Children’s Hospital, Cincinnati, OH, USA),
Rac-F28L (Dr Yi Zheng, Cincinnati Children’s Hospital, Cincinnati, OH, USA),
pIRESpuro3 (Clontech, Mountain View, CA, USA), pIRES-Merlin,7 VAMP2-
GFP was a kind gift from Dr Martin ter Beest (University of Chicago,
Chicago, IL, USA).
Recombinant proteins
Puriﬁed V12HRas-GST, N17Rac-GST and L61Rac-His proteins (Cytoskeleton,
Denver, CO, USA) were each reconstituted at 20 mM in ddH20 and aliquots
stored at  80 1C. Recombinant merlin proteins were puriﬁed as previously
described.7 Each was perfused into axoplasm in Buffer X/2 with the
addition of 5–10mM Hepes, pH7.2 and 5mM ATP.
Cell lines
MEF3ﬂox2 and MEF3D2 cells were described previously.27 SC4 Nf2 /
Schwann cells were obtained from Dr Helen Morrison (Leibniz Institute for
Age Research). Cell lines were maintained in DMEM (Life Technologies,
Grand Island, NY, USA) supplemented with 10% fetal bovine serum
(Gemini Bioproducts, West Sacramento, CA, USA) and 1% Pen/Strep
(HyClone, Logan, UT, USA) at 37 1C, 7.5% CO2.
Primary cell culture
Primary Schwann cells and schwannoma tumor cells were isolated from
normal human nerves and patient-derived schwannomas isolated as
previously described.50,51 For analysis, cells at passage 3–5 were
trypsinized and plated onto poly-L-lysine and laminin-coated glass
coverslips, and transfected with VAMP-GFP using Fugene-6. After
36–48h, cells were imaged directly or after 2 h incubation in designated
inhibitors.
Growth curves
Nf2þ /þMEF3ﬂox2 and Nf2 / MEF3D2 cells each were plated at
50 000 cells per well in replicate six-well plates. Plates were incubated for
6 h, and then were incubated with inhibitor or vehicle in triplicate wells.
Plates were incubated overnight then one set was trypsinized and cells
were counted with a hemocytometer (Day1). Remaining wells were
counted every 48 h until the end of the assay.
Live cell imaging
SC4 cells were plated into 35mm dishes with a cover slip bottom (Mattek,
Ashland, MA, USA), phenol red-free DMEM, 25mM HEPES pH 7.4, 10% FBS,
1% Pen/Strep supplemented with 20mM Trolux (Sigma Aldrich, St Louis,
MO, USA), as an antifade reagent, then transfected with a mixture of 0.5mg
pRab6-mStrawberry and 1.5mg either pIRESpuro 3 (Clontech) empty vector
or expression vector (merlin, Rac or ErbB2) using Fugene-6 (GE BioSciences,
Piscataway, NJ, USA) at a 3:1 Fugene:DNA ratio, as per manufacturer’s
instructions. Images were acquired on a Zeiss Axiovert 200M microscope
equipped with a stage incubator (In Vivo Scientiﬁc, St Louis, MO, USA)
maintaining 37 1C using an Orca ER II camera (Hammamatsu, Bridgewater,
NJ, USA), controlled by MicroManager v1.3 software.52
Image analysis
VAMP2 mobility was measured by determining the percentage of
VAMP2-GFP-positive pixels that changed position relative to total
ﬂuorescence, between each 3 s interval the time lapse. Statistical analysis
by Mann–Whitney non-parametric t-test and graph generation was
performed using Prism (GraphPad, La Jolla, CA, USA).
To image Rab6 vesicle motility, a stack of 60 images were acquired at 1 s
intervals with 200msec exposure with the camera bin set to 2 2 for a
total of 72 s. Image analysis was performed with Image J software (NIH). To
visualize motion, the intensity of small vesicles was enhanced by
subtracting a blurred copy of the image, and then all 60 images of the
time lapse were collated into a single image. To measure the velocity of
individual vesicles, time-lapse stacks were color coded to display
successive frames in red, green and blue, the position of individual
vesicles was lapse was logged and the distance traveled was measured. At
least 21 cells were imaged per replicate with from 10 to 20 tracks
measured per cell for a total of 200–500 velocity measurements per
experiment. Data was collated and analyzed with Excel (Microsoft).
Statistical analysis by Mann–Whitney non-parametric t-test and graph
generation was performed using Prism (GraphPad).
Axoplasm and video microscopy
Axoplasm was extruded from giant axons dissected from squid (Loligo
pealei) supplied by the Marine Biological Laboratory (Woods Hole, MA,
USA) and video microscopy of membrane-bound organelles and perfusion
with recombinant proteins was performed as previously described.34,53,54
CONFLICT OF INTEREST
The authors declare no conﬂict of interest.
ACKNOWLEDGEMENTS
This work was supported by NIH R01 CA118032 (to NR), and MBL research fellowships
(to NR and GM), NIH R01 NS23868 (to STB). We thank Atira Dudley Hardiman for
assistance with growth and transfection of human cells, Jamie M Walker for expert
technical assistance and Dr Yi Zheng for critical reading of the manuscript.
REFERENCES
1 Rouleau GA, Merel P, Lutchman M, Sanson M, Zucman J, Marineau C et al.
Alteration in a new gene encoding a putative membrane-organizing protein
causes neuro-ﬁbromatosis type 2. Nature 1993; 363: 515–521.
2 MacCollin M, Mohney T, Trofatter J, Wertelecki W, Ramesh V, Gusella J. DNA
diagnosis of neuroﬁbromatosis 2. Altered coding sequence of the merlin tumor
suppressor in an extended pedigree. JAMA 1993; 270: 2316–2320.
3 Ammoun S, Hanemann CO. Emerging therapeutic targets in schwannomas and
other merlin-deﬁcient tumors. Nat Rev Neurol [Review] 2011; 7: 392–399.
4 McClatchey AI. Merlin and ERM proteins: unappreciated roles in cancer
development? Nat Rev Cancer 2003; 3: 877–883.
5 Giovannini M, Robanus-Maandag E, van der Valk M, Niwa-Kawakita M,
Abramowski V, Goutebroze L et al. Conditional biallelic Nf2 mutation in the mouse
promotes manifestations of human neuroﬁbromatosis type 2. Genes Dev 2000; 14:
1617–1630.
6 Bretscher A, Edwards K, Fehon RG. ERM proteins and merlin: integrators at the cell
cortex. Nat Rev Mol Cell Biol 2002; 3: 586–599.
7 Hennigan RF, Foster LA, Chaiken MF, Mani T, Gomes MM, Herr AB et al.
Fluorescence resonance energy transfer analysis of merlin conformational chan-
ges. Mol Cell Biol 2010; 30: 54–67.
NF2 and Rac in vesicle transport
RF Hennigan et al
1142
Oncogene (2013) 1135 – 1143 & 2013 Macmillan Publishers Limited
8 Shaw RJ, McClatchey AI, Jacks T. Regulation of the neuroﬁbromatosis type 2
tumor suppressor protein, merlin, by adhesion and growth arrest stimuli. J Biol
Chem 1998; 273: 7757–7764.
9 Alfthan K, Heiska L, Gronholm M, Renkema GH, Carpen O. Cyclic AMP-dependent
protein kinase phosphorylates merlin at serine 518 independently of p21-
activated kinase and promotes merlin-ezrin heterodimerization. J Biol Chem 2004;
279: 18559–18566.
10 Jin H, Sperka T, Herrlich P, Morrison H. Tumorigenic transformation by CPI-17
through inhibition of a merlin phosphatase. Nature 2006; 442: 576–579.
11 Xiao GH, Beeser A, Chernoff J, Testa JR. p21-activated kinase links Rac/Cdc42
signaling to merlin. J Biol Chem 2002; 277: 883–886.
12 Kissil JL, Johnson KC, Eckman MS, Jacks T. Merlin phosphorylation by p21-acti-
vated kinase 2 and effects of phosphorylation on merlin localization. J Biol Chem
2002; 277: 10394–10399.
13 Shaw RJ, Paez JG, Curto M, Yaktine A, Pruitt WM, Saotome I et al. The Nf2 tumor
suppressor, merlin, functions in Rac-dependent signaling. Dev Cell. 2001; 1: 63–72.
14 Pelton PD, Sherman LS, Rizvi TA, Marchionni MA, Wood P, Friedman RA et al.
Rufﬂing membrane, stress ﬁber, cell spreading and proliferation abnormalities in
human Schwannoma cells. Oncogene 1998; 17: 2195–2209.
15 Kaempchen K, Mielke K, Utermark T, Langmesser S, Hanemann CO. Upregulation
of the Rac1/JNK signaling pathway in primary human schwannoma cells. Hum Mol
Genet 2003; 12: 1211–1221.
16 Nakai Y, Zheng Y, MacCollin M, Ratner N. Temporal control of Rac in Schwann cell-
axon interaction is disrupted in NF2-mutant schwannoma cells. J Neurosci 2006;
26: 3390–3395.
17 Morrison H, Sherman LS, Legg J, Banine F, Isacke C, Haipek CA et al. The NF2
tumor suppressor gene product, merlin, mediates contact inhibition of growth
through interactions with CD44. Genes Dev 2001; 15: 968–980.
18 Okada T, Lopez-Lago M, Giancotti FG. Merlin/NF-2 mediates contact inhibition of
growth by suppressing recruitment of Rac to the plasma membrane. J Cell Biol
2005; 171: 361–371.
19 Curto M, Cole BK, Lallemand D, Liu CH, McClatchey AI. Contact-dependent
inhibition of EGFR signaling by Nf2/Merlin. J Cell Biol 2007; 177: 893–903.
20 McClatchey AI, Fehon RG. Merlin and the ERM proteins--regulators of receptor
distribution and signaling at the cell cortex. Trends Cell Biol 2009; 19: 198–206.
21 Sampo B, Kaech S, Kunz S, Banker G. Two distinct mechanisms target membrane
proteins to the axonal surface. Neuron 2003; 37: 611–624.
22 Gerst JE. SNAREs and SNARE regulators in membrane fusion and exocytosis. Cell
Mol Life Sci 1999; 55: 707–734.
23 Singh BB, Lockwich TP, Bandyopadhyay BC, Liu X, Bollimuntha S, Brazer SC et al.
VAMP2-dependent exocytosis regulates plasma membrane insertion of TRPC3
channels and contributes to agonist-stimulated Ca2þ inﬂux. Mol Cell 2004; 15:
635–646.
24 Randhawa VK, Bilan PJ, Khayat ZA, Daneman N, Liu Z, Ramlal T et al. VAMP2, but
not VAMP3/cellubrevin, mediates insulin-dependent incorporation of GLUT4 into
the plasma membrane of L6 myoblasts. Mol Biol Cell 2000; 11: 2403–2417.
25 Gao Y, Dickerson JB, Guo F, Zheng J, Zheng Y. Rational design and character-
ization of a Rac GTPase-speciﬁc small molecule inhibitor. Proc Natl Acad Sci USA
2004; 101: 7618–7623.
26 Bosco DA, Morﬁni G, Karabacak NM, Song Y, Gros-Louis F, Pasinelli P et al.
Wild-type and mutant SOD1 share an aberrant conformation and a common
pathogenic pathway in ALS. Nat Neurosci 2010; 13: 1396–1403.
27 Bosco EE, Nakai Y, Hennigan RF, Ratner N, Zheng Y. NF2-deﬁcient cells depend on
the Rac1-canonical Wnt signaling pathway to promote the loss of contact inhi-
bition of proliferation. Oncogene 2010; 29: 2540–2549.
28 Tibbles LA, Ing YL, Kiefer F, Chan J, Iscove N, Woodgett JR et al. MLK-3 activates
the SAPK/JNK and p38/RK pathways via SEK1 and MKK3/6. EMBO J 1996; 15:
7026–7035.
29 Lallemand D, Manent J, Couvelard A, Watilliaux A, Siena M, Chareyre F et al. Merlin
regulates transmembrane receptor accumulation and signaling at the plasma
membrane in primary mouse Schwann cells and in human schwannomas.
Oncogene 2009; 28: 854–865.
30 Grigoriev I, Splinter D, Keijzer N, Wulf PS, Demmers J, Ohtsuka T et al. Rab6
regulates transport and targeting of exocytotic carriers. Dev Cell 2007; 13: 305–314.
31 Lerdrup M, Hommelgaard AM, Grandal M, van Deurs B. Geldanamycin stimulates
internalization of ErbB2 in a proteasome-dependent way. J Cell Sci 2006;
119(Part 1): 85–95.
32 Best A, Ahmed S, Kozma R, Lim L. The Ras-related GTPase Rac1 binds tubulin.
J Biol Chem 1996; 271: 3756–3762.
33 Morﬁni GA, Burns M, Binder LI, Kanaan NM, LaPointe N, Bosco DA et al.
Axonal transport defects in neurodegenerative diseases. J Neurosci 2009; 29:
12776–12786.
34 Brady ST, Lasek RJ, Allen RD. Video microscopy of fast axonal transport in
extruded axoplasm: a new model for study of molecular mechanisms. Cell Motil
1985; 5: 81–101.
35 Morﬁni G, Pigino G, Szebenyi G, You Y, Pollema S, Brady ST. JNK mediates
pathogenic effects of polyglutamine-expanded androgen receptor on fast axonal
transport. Nat Neurosci 2006; 9: 907–916.
36 Morﬁni GA, You YM, Pollema SL, Kaminska A, Liu K, Yoshioka K et al. Pathogenic
huntingtin inhibits fast axonal transport by activating JNK3 and phosphorylating
kinesin. Nat Neurosci 2009; 12: 864–871.
37 Li W, You L, Cooper J, Schiavon G, Pepe-Caprio A, Zhou L et al. Merlin/NF2
suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in
the nucleus. Cell 2010; 140: 477–490.
38 Maitra S, Kulikauskas RM, Gavilan H, Fehon RG. The tumor suppressors merlin and
Expanded function cooperatively to modulate receptor endocytosis and signal-
ing. Curr Biol 2006; 16: 702–709.
39 Cole BK, Curto M, Chan AW, McClatchey AI. Localization to the cortical
cytoskeleton is necessary for Nf2/merlin-dependent epidermal growth factor
receptor silencing. Mol Cell Biol 2008; 28: 1274–1284.
40 Woodcock SA, Rushton HJ, Castaneda-Saucedo E, Myant K, White GR, Blyth K et al.
Tiam1-Rac signaling counteracts Eg5 during bipolar spindle assembly to facilitate
chromosome congression. Curr Biol 2010; 20: 669–675.
41 Chen YA, Scheller RH. SNARE-mediated membrane fusion. Nat Rev Mol Cell Biol
[Review] 2001; 2: 98–106.
42 Bos JL, Rehmann H, A Wittinghofer. GEFs and GAPs: critical elements in the
control of small G proteins. Cell 2007; 129: 865–877.
43 Avruch J. MAP kinase pathways: The ﬁrst twenty years. Bba-Mol Cell Rea 2007
1150–1160.
44 Gallo KA, Johnson GL. Mixed-lineage kinase control of JNK and p38 MAPK
pathways. Nat Rev Mol Cell Biol. [Review] 2002; 3: 663–672.
45 Teramoto H, Coso OA, Miyata H, Igishi T, Miki T, Gutkind JS. Signaling from the
small GTP-binding proteins Rac1 and Cdc42 to the c-Jun N-terminal kinase/stress-
activated protein kinase pathway. A role for mixed lineage kinase 3/protein-
tyrosine kinase 1, a novel member of the mixed lineage kinase family. J Biol Chem
1996; 271: 27225–27228.
46 Nagata K, Puls A, Futter C, Aspenstrom P, Schaefer E, Nakata T et al. The MAP
kinase kinase kinase MLK2 co-localizes with activated JNK along microtubules and
associates with kinesin superfamily motor KIF3. EMBO J. 1998; 17: 149–158.
47 Muranen T, Gronholm M, Lampin A, Lallemand D, Zhao F, Giovannini M et al. The
tumor suppressor merlin interacts with microtubules and modulates Schwann cell
microtubule cytoskeleton. Hum Mol Genet 2007; 16: 1742–1751.
48 Bensenor LB, Barlan K, Rice SE, Fehon RG, Gelfand VI. Microtubule-mediated
transport of the tumor-suppressor protein merlin and its mutants. Proc Natl Acad
Sci USA 2010; 107: 7311–7316.
49 Lerdrup M, Bruun S, Grandal MV, Roepstorff K, Kristensen MM, Hommelgaard AM
et al. Endocytic down-regulation of ErbB2 is stimulated by cleavage of its
C-terminus. Mol Biol Cell 2007; 18: 3656–3666.
50 Rutkowski JL, Kirk CJ, Lerner MA, Tennekoon GI. Puriﬁcation and expansion of
human Schwann cells in vitro. Nat Med 1995; 1: 80–83.
51 Rosenbaum C, Kluwe L, Mautner VF, Friedrich RE, Muller HW, Hanemann CO.
Isolation and characterization of Schwann cells from neuroﬁbromatosis type 2
patients. Neurobiol Dis 1998; 5: 55–64.
52 Edelstein A, Amodaj N, Hoover K, Vale R, Stuurman N. Computer Control of
Microscopes Using mManager. John Wiley & Sons, Inc, 2010.
53 Brady ST, Pﬁster KK, Bloom GS. A monoclonal antibody against kinesin inhibits
both anterograde and retrograde fast axonal transport in squid axoplasm. Proc
Natl Acad Sci USA 1990; 87: 1061–1065.
54 Stenoien DL, Brady ST. Immunochemical analysis of kinesin light chain function.
Mol Biol Cell 1997; 8: 675–689.
This work is licensed under the Creative Commons Attribution-
NonCommercial-No Derivative Works 3.0 Unported License. To view a
copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/
Supplementary information accompanies the paper on the Oncogene website (http://www.nature.com/onc)
NF2 and Rac in vesicle transport
RF Hennigan et al
1143
& 2013 Macmillan Publishers Limited Oncogene (2013) 1135 – 1143
